GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exelixis Inc (FRA:EX9) » Definitions » Cash Receipts from Securities Related Activities

Exelixis (FRA:EX9) Cash Receipts from Securities Related Activities


View and export this data going back to 2000. Start your Free Trial

What is Exelixis Cash Receipts from Securities Related Activities?

Cash Receipts from Securities Related Activities only applicable to companies reporting Cash Flow from Operations in direct method.


Exelixis (FRA:EX9) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exelixis Inc (FRA:EX9) » Definitions » Cash Receipts from Securities Related Activities
Traded in Other Exchanges
Address
1851 Harbor Bay Parkway, Alameda, CA, USA, 94502
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.